[ad_1]
<div id = "firstBodyDiv" data-bind-html-content-type = "article" data-bind-html-compile = "article.body" data-first-article-body = "
According to the report "Jerusalem Post", The researchers are supervised by the CEO of the pharmaceutical company "AEBI", Ilan Murad, confirm that they have taken several steps in their project.
The researchers called treatment B "Mo Tatu" And this medical method develops a toxic substance that kills Cancer cells Only, without infecting healthy cells.
The medical project adds that patients Who will be subject to this Treatment "Revolutionary" In just a few weeks, they will no longer have to take the drug for long periods.
The new therapeutic approach to cancer focuses on the compatibility of peptides (a series of acids that attack cancer) and the toxic substance that destroys cancer cells.
According to the company's president, Dan Arredor, the treatment will have no side effects other than what is currently happening in the treatment of cancer and will be available at a low cost compared to market treatments.
The scientific team conducted their first experiments on a sample of Experimental miceThe results are very promising, but the company needs to do more clinical tests in a few years.
">
According to the Jerusalem Post, researchers supervised by the AEBI's director general, Ilan Murat, confirm that they have gone through several stages in their project.
The researchers called the treatment "Mo Tatu", and this method of medical development of a toxin that kills only cancer cells, without infecting healthy cells.
The medical project adds that patients who undergo this "revolutionary" treatment in just a few weeks will not have to take the drug for long periods.
The new therapeutic approach to cancer focuses on the compatibility of peptides (a series of acids that attack cancer) and the toxic substance that destroys cancer cells.
According to the company's president, Dan Arredor, the treatment will have no side effects other than what is currently happening in the treatment of cancer and will be available at a low cost compared to market treatments.
The team conducted its first experiments on a sample of test mice, claiming that the results were very promising, but that the company had to do more clinical trials in a few years.
